Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134315 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL583320 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL980555 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL3415840 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL1149470 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL23320287 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Bromide SCHEMBL583318 | 0.96 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL8209880 | 0.96 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL4771744 | 0.96 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL10000695 | 0.93 | SIGMAR1 (0.45) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | claimed |
| WO-2026090330-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725946-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5439904-A | Enzyme inhibitors of human leukocyte elastase; respiratory system disorders; antiarthritic agents | SYNPHAR LABORATORIES, INC. (CA) | 1995-08-08 | — | — | US | disclosed |
| WO-1995015966-A1 | 2-SPIRO(2'-SPIROCYCLOALKYL)CYCLOPROPYL CEPHALOSPORIN SULFONES AS ANTIINFLAMMATORY AND ANTIDEGENERATIVE AGENTS | SYNPHAR LABORATORIES, INC. (CA) | 1995-06-15 | — | — | WO | disclosed |
| CN-1083475-A | Acetogenin | GLAXO GROUP LTD (GB) | 1994-03-09 | — | — | CN | disclosed |
| EP-0581789-A1 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES INC. (CA) | 1994-02-09 | — | — | EP | disclosed |
| US-5264430-A | Enzyme inhibitor, antiinflammatory agents, treats emphysema, cystic fibrosis and arthritis | SYNPHAR LABORATORIES, INC. (CA) | 1993-11-23 | — | — | US | disclosed |
| US-5264429-A | Enzyme inhibitor, antiinflammatory agents, treats emphysema, cystic fibrosis and arthritis | SYNPHAR LABORATORIES, INC. (CA) | 1993-11-23 | — | — | US | disclosed |
| WO-1992018474-A2 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES, INC. (CA) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | SIGMAR1 419/4885CHRM3 4389/4885CHRM5 4096/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | SIGMAR1 1072/4885CHRM3 3354/4885CHRM5 3438/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | SIGMAR1 2111/4885CHRM3 4280/4885CHRM5 4004/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | SIGMAR1 522/4885CHRM3 2346/4885CHRM5 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.